J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and APIs in India and internationally.
Flawless balance sheet with solid track record and pays a dividend.
Share Price & News
How has J. B. Chemicals & Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 506943's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 506943 exceeded the Indian Pharmaceuticals industry which returned -14.8% over the past year.
Return vs Market: 506943 exceeded the Indian Market which returned -32.1% over the past year.
Price Volatility Vs. Market
How volatile is J. B. Chemicals & Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is J. B. Chemicals & Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 506943 (₹448.2) is trading below our estimate of fair value (₹522.79)
Significantly Below Fair Value: 506943 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 506943 is poor value based on its PE Ratio (13.5x) compared to the Pharmaceuticals industry average (11.7x).
PE vs Market: 506943 is poor value based on its PE Ratio (13.5x) compared to the Indian market (9.4x).
Price to Earnings Growth Ratio
PEG Ratio: 506943 is poor value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: 506943 is overvalued based on its PB Ratio (2.3x) compared to the IN Pharmaceuticals industry average (1.1x).
How is J. B. Chemicals & Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 506943's forecast earnings growth (13% per year) is above the savings rate (6.5%).
Earnings vs Market: 506943's earnings (13% per year) are forecast to grow slower than the Indian market (19.2% per year).
High Growth Earnings: 506943's earnings are forecast to grow, but not significantly.
Revenue vs Market: 506943's revenue (12.4% per year) is forecast to grow faster than the Indian market (8.8% per year).
High Growth Revenue: 506943's revenue (12.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 506943's Return on Equity is forecast to be low in 3 years time (18.8%).
How has J. B. Chemicals & Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 506943 has high quality earnings.
Growing Profit Margin: 506943's current net profit margins (15.3%) are higher than last year (11.3%).
Past Earnings Growth Analysis
Earnings Trend: 506943's earnings have grown by 14.3% per year over the past 5 years.
Accelerating Growth: 506943's earnings growth over the past year (49.3%) exceeds its 5-year average (14.3% per year).
Earnings vs Industry: 506943 earnings growth over the past year (49.3%) exceeded the Pharmaceuticals industry 22%.
Return on Equity
High ROE: 506943's Return on Equity (17%) is considered low.
How is J. B. Chemicals & Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 506943's short term assets (₹12.2B) exceed its short term liabilities (₹3.1B).
Long Term Liabilities: 506943's short term assets (₹12.2B) exceed its long term liabilities (₹587.3M).
Debt to Equity History and Analysis
Debt Level: 506943's debt to equity ratio (3%) is considered satisfactory.
Reducing Debt: 506943's debt to equity ratio has reduced from 11.8% to 3% over the past 5 years.
Debt Coverage: 506943's debt is well covered by operating cash flow (583.5%).
Interest Coverage: 506943 earns more interest than it pays, so coverage of interest payments is not a concern.
What is J. B. Chemicals & Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 506943's dividend (2.23%) is higher than the bottom 25% of dividend payers in the Indian market (0.96%).
High Dividend: 506943's dividend (2.23%) is low compared to the top 25% of dividend payers in the Indian market (4.06%).
Stability and Growth of Payments
Stable Dividend: 506943's dividend payments have been volatile in the past 10 years.
Growing Dividend: 506943's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (15%), 506943's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 506943's dividends in 3 years are forecast to be thoroughly covered by earnings (14.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jyotindra Mody (90yo)
Mr. Jyotindra Bhagwanlal Mody serves as Chairman and Managing Director at J. B. Chemicals & Pharmaceuticals Ltd. Mr. Mody has experience of over four decades in the Indian pharmaceutical industry. Mr. Mody ...
CEO Compensation Analysis
Compensation vs Market: Jyotindra's total compensation ($USD839.82K) is above average for companies of similar size in the Indian market ($USD344.71K).
Compensation vs Earnings: Jyotindra's compensation has increased by more than 20% in the past year.
|Chairman & MD||no data||₹64.08m||6.99% ₹2.4b|
|President||no data||₹28.11m||9.51% ₹3.3b|
|Director of Technical & Production and Executive Director||no data||₹18.18m||0.071% ₹24.5m|
|Director of Marketing & Whole-Time Director||no data||₹64.08m||6.02% ₹2.1b|
|Director of Planning & Development and Whole-Time Director||no data||₹28.11m||3.16% ₹1.1b|
|Chairman of Biotech Laboratories (Pty ) Ltd||no data||no data||no data|
|Non-Executive & Independent Director||14.92yrs||₹480.00k||0.0022% ₹772.4k|
|Independent Director||9.75yrs||₹980.00k||0.0020% ₹703.1k|
|Independent Director||6.25yrs||₹900.00k||no data|
|Non-Executive Independent Director||5.33yrs||₹660.00k||0.022% ₹7.6m|
Experienced Board: 506943's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 506943 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
J. B. Chemicals & Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
- Name: J. B. Chemicals & Pharmaceuticals Limited
- Ticker: 506943
- Exchange: BSE
- Founded: 1976
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹34.638b
- Shares outstanding: 77.28m
- Website: https://www.jbcpl.com
- J. B. Chemicals & Pharmaceuticals Limited
- Cnergy IT Park
- Unit A2, 3rd floor & Unit A, 8th floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|506943||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Dec 2001|
|JBCHEPHARM||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Dec 2001|
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and APIs in India and internationally. The company manufactures a range of specialty products that include various pharmaceutical dosage forms. Its principal products include Cilnidipine, Ranitidine, and Metronidazole. The company also provides contract manufacturing services for tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and medicated and herbal lozenges. J. B. Chemicals & Pharmaceuticals Limited was founded in 1976 and is headquartered in Mumbai, India.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/07 12:56|
|End of Day Share Price||2020/04/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.